Chlamydia trachomatis vaccines for genital infections: where are we and how far is there to go?. (3rd April 2021)

• Record Type: Journal Article
• Authors: de la Maza, Luis M.; Darville, Toni L; Pal, Sukumar
• Is Part Of: Expert review of vaccines. Volume 20:Number 4(2021)
• Page Start: 421
• Page End: 435
• Publication Date: 2021-04-03
• Subjects: Chlamydia muridarum -- Chlamydia trachomatis -- vaccines -- immunization -- antigens -- adjuvants -- routes of immunization -- delivery systems -- mouse model -- sexually transmitted infections; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1080/14760584.2021.1899817
• Languages: English
• ISSNs: 1476-0584

Abstract

ABSTRACT: Introduction: Chlamydia trachomatis is the most common sexually transmitted bacterial pathogen in the world. Antibiotic treatment does not prevent against reinfection and a vaccine is not yet available. Areas covered: We focus the review on the progress made of our understanding of the immunological responses required for a vaccine to elicit protection, and on the antigens, adjuvants, routes of immunization and delivery systems that have been tested in animal models. PubMed and Google Scholar were used to search publication on these topics for the last 5 years and recent Reviews were examined. Expert opinion: The first Phase 1 clinical trial of a C. trachomatis vaccine to protect against genital infections was successfully completed. We expect that, in the next five years, additional vaccine clinical trials will be implemented.